Semaglutide & Tirzepatide Reduce Fall and Femoral Fracture Risk in Older Adults with Type 2 Diabetes (2026)

For patients considering semaglutide or tirzepatide, the conversation often centers on blood sugar control and weight loss. But a compelling 2026 study published in *Osteoporosis International* reveals something that may matter even more to older adults: these GLP-1 and GIP/GLP-1 receptor agonists appear to significantly reduce the risk of falls and femoral fractures compared to a widely used class of diabetes medications. For anyone over 65 managing type 2 diabetes, this finding adds a meaningful layer of musculoskeletal protection to an already impressive therapeutic profile.

This retrospective cohort study, conducted by Chen, Wu, Chu, and colleagues at Chi Mei Medical Center and affiliated institutions in Taiwan, analyzed real-world data from the TriNetX database spanning 2018 to 2025. The researchers focused on adults aged 65 and older who had been diagnosed with type 2 diabetes (T2DM) and were either overweight or obese (BMI ≥ 25 kg/m²).

Patients treated with semaglutide or tirzepatide were matched 1:1 using propensity score matching against patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors — a common, well-established oral diabetes medication class. After matching, the semaglutide comparison group included 27,896 patients and the tirzepatide comparison group included 12,808 patients. The primary outcome measured was femoral fracture at one year; falls served as a secondary outcome.

Falls and femoral fractures represent two of the most serious — and most preventable — threats to independence and survival in older adults. A hip or femoral fracture in a patient over 65 carries a one-year mortality rate of up to 30% in some populations. Standard diabetes management has historically focused on glycemic control with relatively little attention to these downstream skeletal risks.

This study is significant because it positions incretin-based therapies — specifically GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 receptor agonists like tirzepatide — as agents with meaningful musculoskeletal benefits that extend well beyond blood sugar management. While the exact mechanisms remain under investigation, proposed pathways include improvements in body composition (preserving lean mass relative to fat), enhanced neuromuscular function, reduction in systemic inflammation, and potential direct effects of GLP-1 receptors expressed in bone and muscle tissue.

Importantly, the comparison group in this study was DPP-4 inhibitors — not a placebo. DPP-4 inhibitors are themselves considered a reasonable and generally well-tolerated diabetes drug class. The fact that semaglutide and tirzepatide outperformed them on musculoskeletal outcomes strengthens the argument that these newer agents offer a genuinely differentiated clinical advantage.

If you are an older adult managing type 2 diabetes — or if you have a parent or loved one in that situation — this research offers a meaningful data point when evaluating treatment options. Choosing a medication like semaglutide or tirzepatide may provide simultaneous benefits across glycemic control, body weight, cardiovascular risk, and now potentially bone and fall safety.

From a longevity medicine standpoint, preventing a single serious fall or fracture can preserve years of functional independence. When I evaluate patients for peptide-based therapies, musculoskeletal resilience is always part of the conversation. This study reinforces that the benefits of these agents are systemic — not siloed to one organ or outcome. Patients with BMI ≥ 30 kg/m² appeared to derive even greater fracture protection, which is particularly relevant given how commonly obesity and T2DM co-occur in older patients seeking metabolic support.

As with all retrospective, database-driven research, several limitations deserve acknowledgment:

These limitations do not diminish the findings, but they do underscore the need for prospective, randomized trials to confirm and mechanistically explain the musculoskeletal benefits observed here.